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Background: People who inject drugs (PWID) are at risk of hepatitis C virus (HCV). It is plausible that 
PWID who receive a diagnosis of HCV will reduce their injecting risk out of concern for their injecting 
partners, although evidence for this is currently limited. The aim of this study was to investigate whether 
informing PWID of their HCV diagnosis was associated with a change in injecting behaviour. 
Methods: Prospective, longitudinal study of PWID recruited from street drug markets across Melbourne, 
Australia. Interviews and HCV testing were conducted at 3-monthly intervals. The association between 
receiving a diagnosis of HCV and (i) injecting frequency and (ii) injecting equipment borrowing, was 
examined using generalized estimating equations (GEE) analysis. 
Results: Thirty-five individuals received a diagnosis of HCV during the study period. Receiving a diagnosis of 
HCV was associated with a decrease of 0.35 injections per month (p = 0.046) but there was no change in 
injecting equipment borrowing (p = 0.750). 
Conclusions: A small reduction in injecting frequency was observed in PWID who received a diagnosis of 






Hepatitis C virus (HCV) is a significant cause of morbidity and mortality amongst people who inject drugs 
(PWID) (Grebely & Dore, 2011). Screening PWID for HCV infection has been rec- ommended as a 
means of supporting infected individuals into appropriate care pathways, and providing advice on safer 
injecting practice to reduce HCV transmission (WHO, 2011). It seems plausi- ble that PWID who are diagnosed 
with HCV, and receive counselling on the risks of HCV transmission, will subsequently reduce their injecting 
risk behaviour in order to decrease their chance of trans- mitting HCV to others. 
Few studies have examined the impact of HCV diagnosis on injecting behaviour: Tsui et al. (2009) found 
no change in inject- ing drug use, equipment sharing, or equipment lending amongst a cohort of young 
PWID followed over a 12-month period, and Ompad, Fuller, Vlahvov, Thomas, and Strathdee (2002) reported 
no change in the sharing of needles, syringes or other injection para- phernalia six months after receiving a 
diagnosis of HCV. Aitken, Kerger, and  Crofts  (2002) found  an  increase  in the  use  of  new needles and 
syringes three months following HCV testing and counselling, but there was no difference between people 
receiv- ing positive or negative HCV results. However, these studies were limited by relatively short periods of 
follow-up. 
The Networks II study followed a cohort of PWID over a period of five years, with the aim of 
understanding the transmission of blood borne viruses (BBV) amongst a social network of PWID. The aim of 
this study was to determine whether, in this cohort of PWID, informing an individual of their HCV diagnosis was 






PWID who reported that they had injected in the previous six months were recruited from three major 
street drug markets  located across Melbourne. PWID aged 16–25 years, or who were not infected with HCV, 
were preferentially recruited. Participation was voluntary, and informed consent in writing was obtained 
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from each participant. The Victorian Department of Human Services Human Research Ethics Committee 




Participants were recruited between July 2005 and 2007, with follow-up continuing until December 
2010. At baseline and three-monthly intervals, participants underwent venepuncture and face-to-face 
interviews with outreach workers trained in pre and post-test discussions for blood borne viruses (BBVs). 
At each visit, participants were asked (i) how often they had injected in the previous month and (ii) the 
number of times injected in the previ- ous three months using a needle and syringe that had already been 
used by someone else (hereafter referred to as ‘borrowing’). 
Blood samples were screened for anti-HCV antibody (anti-HCV) by a third-generation enzyme 
immunoassay (Abbott Laborato- ries, Chicago, IL) and positive specimens were confirmed using the 
Murex anti-HCV antibody test, version 4.0 (Murex Biotech, Kyalami, South Africa). Irrespective of anti-
HCV status, all sam- ples were tested for HCV RNA using COBAS AMPLICOR HCV test version 2.0 (Roche 
Molecular Systems, Branchburg, NJ). Individ- uals testing negative for anti-HCV were tested for anti-HCV 
and HCV RNA at subsequent visits. Individuals testing positive for anti- HCV were retested for HCV RNA, but not 
antibody, at subsequent visits. Participant interviews lasted on average 30–40 min (includ- ing 
venepuncture), and participants were reimbursed AU$25 cash for each interview attended. 
 
Pre and post-test discussion 
 
The pre-test discussion was provided by trained interviewers and has been described in detail 
elsewhere (Winter et al., 2008).  The aims were to ensure the participant was aware of the pros and cons of 
being tested, to investigate the support required in the event of a positive test, and to provide information on 
the transmission and prevention of HCV. 
Efforts to contact participants were made as soon as test results became available, which was normally 
within two to four weeks of testing. In a small number of cases, participants could not imme- diately be 
contacted, and test results were provided more than four weeks after the test date. Participants 
receiving a positive HCV RNA test for the first time were provided with information about the 
interpretation of the test results, strategies for minimiz- ing the risk of HCV transmission, and appropriate 
steps for further assessment of their HCV by a healthcare professional. Printed HCV educational materials and 




Within the Networks II study, we identified individuals who had a baseline and at least two follow-up visits 
(and corresponding blood results for HCV serostatus) to generate three time points (in order to observe trends 
in injecting behaviour post HCV diagnosis). Two groups were defined. The ‘Diagnosed during study’ group 
comprised of individuals who received a new diagnosis of HCV during the study period. This included 
individuals who (i) serocon- verted during the study or (ii) were HCV RNA positive at study entry but stated at 
baseline interview that they had either never tested for HCV, or that they believed they were HCV negative. The 
‘Not diag- nosed during study’ group comprised of the remaining individuals who did not receive a diagnosis of 
HCV during the study period, but 
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could still be anti-HCV or HCV RNA positive (if they were already aware of their HCV diagnosis when they 
entered the study). 
Baseline characteristics of participants who had at least three time points were compared with 
participants who had less than three  time  points  using  a  Wilcoxon  rank-sum  for  continuous variables, 
and chi-square tests for categorical variables. Baseline characteristics of the ‘Diagnosed during study’ group, 
and the ‘Not diagnosed during study’ group were compared in the same manner. Associations   between   time   
since   diagnosis,   pre-diagnosis behaviour, and gender, and (i) injecting frequency and (ii) inject- ing  
equipment  borrowing  were  investigated  using  generalized estimating equations (GEE). The study sample 
size limited multi- variable modelling to three concurrent predictors in any one model. Selection of the model 
correlation structure and model selection was undertaken using the Quasi-likelihood Information Criterion 
(QIC). All reported p values were exact and two-tailed, with p < 0.05 considered significant. All analyses were 
performed using STATA 




Of 413 individuals enrolled in the cohort, 199 individuals had at least three data points for analysis. Those 
with three data points were comparable to those with less than three data points, except for median age 
(25.3 years and 26.0 years respectively, p = 0.044) (Table 1). 
Amongst the 199 individuals, 35 individuals received a diagnosis of HCV, and 164 did not. Of the 35 
individuals in the ‘Diagnosed during study’ group, 12 individuals seroconverted during the time period of the 
cohort, and 23 individuals received a diagnosis of HCV infection at baseline (blood test results at study entry 
showed HCV infection, but the participant stated at baseline interview that they were not aware of their HCV 
status or that they were HCV negative). The 23 who were already HCV RNA positive at study entry were 
comparable to those who seroconverted during the study, except for reporting longer injecting careers 
(median 10.3 years and 5.1 years respectively, p = 0.040). There were no significant differences between 
the characteristics of individuals in the ‘Diagnosed during study’ and the ‘Not diagnosed during study’ groups. 
 
Injecting frequency in the ‘Diagnosed during study’ group 
 
In univariable analysis, every one month since diagnosis of a positive HCV result was associated with a 
decrease of 0.48 injec- tions per month (p = 0.016). In the multivariable model, which corrected for pre-
diagnosis injecting frequency and gender, every month since diagnosis was associated with a decrease of 0.35 
injec- tions per month (p = 0.046) (Table 2). 
 
Equipment borrowing in the ‘Diagnosed during study’ group 
 
In the univariable analysis, there was no statistically signif- icant association between months since 
diagnosis and injecting equipment borrowing. This remained non-significant in the mul- tivariable model, 
which corrected for pre-diagnosis equipment borrowing and gender. 
Separate multivariable models were used to investigate other variables, including age, length of 
injecting career and heroin use (data not shown), and all were non-significant. 
 
Investigating potential cohort effects 
 
We subsequently considered whether the observed reduc- tion in injecting risk behaviour in the 
‘Diagnosed during study’ group was due to participation in the cohort. We therefore con- ducted a GEE 
analysis to examine the association between injecting 
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Male (%) 126 (63.3%) 151 (70.6%) 0.118 26 (74.3) 100 (60.9) 0.19
 




















Length of injecting career (years)* 8.3 (5.0–
 






Injected heroin most in last three 
  
139 (70.2) 150 (70.4) 0.961 24 (68.6) 115 (70.1) 0.85
 
Born in Australia (%) 150 (75.4) 157 (74.1) 0.758 27 (77.1) 124 (75.6) 0.99
 
Received pharmacotherapy during study 
  
101 (50 8)a 96 (44 9)a 0 231a 28 (80.0) 142 (86.6) 0.46
 
Baseline HCV antibody positivity (%) 130 (65.3%) 123 (70.3%) 0.306 23 (65.7) 107 (65.2) 0.99
 










Baseline frequency of borrowing in 
   
0 (0–1.0) 0 (0–1.0) 0.925 0 (0–1.5) 0 (0–1.0) 0.47
 
Note: Data are presented as median 
(25–75% percentiles)* or n (%). 
a  Pharmacotherapy at baseline rather 
than during study period. 
 
 
behaviour and time since study entry in the ‘Diagnosed during study’ group (n = 35) and the ‘Not diagnosed 
during study’ group (n = 164). 
We found that the ‘Diagnosed during study’ group showed a significant reduction in injecting frequency 
over time since study entry (p = 0.047), but the ‘Not diagnosed during study’ group did not (p = 0.093). With 
regards equipment borrowing, we observed no significant change in either the ‘Diagnosed during study’ 






We observed a small reduction in injecting frequency but no change in injecting equipment borrowing 
following a diagnosis of HCV amongst a cohort of PWID in Melbourne, Australia. Previous studies have shown 
no change in injecting risk following a positive HCV test, although these studies had shorter periods of 
follow- up and did not examine injecting frequency (Aitken et al., 2004; Ompad et al., 2002; Tsui et al., 
2009). 
There were a number of limitations to our study. The sample size was small, and follow-up for at least 
three interviews was relatively low. The small sample size meant that it was not possible to account for a 
number of factors (such as opioid substitution ther- apy) that may have impacted on injecting behaviour. 
Further, it is not possible to rule out that the observed reduction in inject- ing frequency was due to a 
cohort effect, although we observed no significant reduction in injecting frequency over time since study 
entry in the ‘Not diagnosed during study’ group. 
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Amongst the ‘Diagnosed during study group’, only 12 individ- uals actually seroconverted during the 
study, and the remaining individuals were diagnosed with HCV infection at their base- line interview. 
Some individuals may therefore have already been aware of their diagnosis, even though they 
reported that they were unaware. Conversely, over half of the ‘Not diagnosed during study group’ were 
actually already HCV antibody positive, because they reported that they had received a diagnosis of HCV 
prior to entering the study. However, we might expect both of these limitations to dilute, rather than 
overestimate, the asso- ciation we have observed between HCV diagnosis and injecting behaviour. 
The average reduction in injection frequency of 0.35 injections per month is small, although this 
reduction needs to be inter- preted in the context of the follow-up time across which this estimate 
was derived. An average reduction of 0.35 injections per month across the entire observation period 
(with a median follow-up of three years) translates into an average reduction of 
12.6 injections across the three years. If starting from a base- line of 40 injections per month (which 
was the average baseline in our cohort), there would be a reduction to 27 injections per month by the 
end of the study period, a reduction of almost one-third. 
However, a reduction in injecting frequency does not necessarily translate into a reduction in risk without a 
concurrent reduction in sharing episodes. We observed no significant change in needle and syringe 
borrowing in this study, although the level of borrowing at baseline was already very low. Qualitative 
evidence suggests that PWID diagnosed with HCV are less likely to be concerned about bor- rowing injecting 
equipment from others, on the assumption that they are already infected (Craine, Walker, Carnwath, & 
Klee, 2004). Counselling of HCV positive individuals should therefore empha- size the ongoing risk posed 
by other BBV, as well as the risk of onward transmission of HCV to other injecting partners. It might be 
expected that being diagnosed with HCV would have a greater impact on lending (rather than borrowing) of 
injecting equipment. However, the post hoc nature of this analysis meant we were unable to examine the 
impact of HCV diagnosis on injecting equipment lending. 
We observed a small reduction in injecting frequency amongst a cohort of PWID diagnosed with HCV, over 
a five-year period offollow-up. This finding should be investigated further in larger studies examining a 
wider range of injecting risk behaviours. 
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